This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.

Inclusion Criteria:

• Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90)

• Are ≥18 years of age at the index date

• Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy

• Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure

• Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure:

  • Pomalidomide-containing regimens:

• Daratumumab, pomalidomide, and dexamethasone (DPd)

• Carfilzomib, pomalidomide, and dexamethasone (KPd)

  • Non-pomalidomide-containing regimens:

• Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only)

• Daratumumab, bortezomib, and dexamethasone (DVd)

• Daratumumab, carfilzomib, and dexamethasone (DKd)

Exclusion Criteria:

• Have <6 months of follow-up from the index date; participants who died will be included even with <6 months follow-up, but participants who died within 1 month after the index date will be excluded

• Have <6 months pre-index enrollment

• Have other primary cancer diagnoses within 1 year pre-index

  • Excluded ICD-10 diagnosis codes: C00.xx-C76.xx, C7A, C80.xx-C88.xx, C91.xx-C96.xx, D00.xx-D09.xx, D37.xx-D47.1x, D47.3x-D49.xx
  • Excluded ICD-9 diagnosis codes: 149.x through 239.x
  • ICD codes 209.4, 209.5, 209.6, 209.7, D47.Z1, D47.Z2, and D3A will not be excluded

• Received chimeric antigen receptor T-cell therapy or bispecific antibody therapy before index date or as the index line

• Have ever enrolled in a clinical trial

Adults with relapsed/refractory multiple myeloma treated in the OneOncology United States database who previously received both a lenalidomide-containing regimen and a proteasome inhibitor and subsequently initiated specified pomalidomide-containing or non-pomalidomide-containing regimens in the second-line or third-line setting.